Jin et al. [38] observed RUNX3 promoter hypermethylation in tumor tissue samples from patients with CS, which resulted in decreased RUNX3 mRNA levels and was correlated with a poor prognosis. This evidence concerns the gene RUNX3 and neoplasm.